Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis

Resource type
Journal Article
Authors/contributors
Title
Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis
Abstract
A registered (PROSPERO - CRD42022346462) systematic review and meta-analysis was conducted of all-grade infections amongst adult patients receiving CAR-T therapy for haematological malignancy. Meta-analysis of pooled incidence, using random effects model, was conducted. Cochran’s Q test examined heterogeneity. 2678 patients across 33 studies were included in the primary outcome. Forty-percent of patients (95% CI: 0.33 – 0.48) experienced an infection of any grade. Twenty-five percent of infection events (95% CI: 0.16 – 0.34) were severe. Late infections were as common as early infections (IRR = 0.86, 95% CI: 0.38 – 1.98). All-grade infections, bacterial and viral infections were highest in myeloma patients at 57%, 37% and 28% respectively. Patients with NHL more commonly experienced late infections. Pooled rate of invasive candidiasis/yeast infections was 2% in studies utilizing anti-yeast prophylaxis. This review identified a high rate of all-grade infections, moderate rate of severe infections, and myeloma as a high-risk haematological group.
Publication
Critical Reviews in Oncology/Hematology
Date
2023-09-20
Pages
104134
Journal Abbr
Critical Reviews in Oncology/Hematology
Accessed
9/29/23, 5:50 PM
ISSN
1040-8428
Short Title
Infections in haematology patients treated with CAR-T therapies
Library Catalog
ScienceDirect
Citation
Reynolds, G. K., Sim, B., Spelman, T., Thomas, A., Longhitano, A., Anderson, M. A., Thursky, K., Slavin, M., & Teh, B. W. (2023). Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 104134. https://doi.org/10.1016/j.critrevonc.2023.104134
HEME-ONC AND CELLULAR THERAPIES
Link to this record